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Introduction: Disulfiram (DSF), a drug used in the treatment of alcoholism since 1948, has 
been shown to have antitumor properties in various tumor types possibly due to the induction 
of a type cell death, ferroptosis, and the sensitization of cells to chemo- and radiotherapy. In 
this study, we explored the antitumor properties of DSF in glioblastoma (GBM) and 
investigated the underlying molecular mechanisms.
Methods: GBM cell lines U251 and LN229 were treated with DSF to assess cytotoxicity 
and activity of the molecule in vitro. Response of cells to treatment was examined using cell 
viability, flow cytometry, LDH release assay, immunofluorescence and Western blot analysis.
Results: DSF inhibited cell growth of GBM U251 and LN229 cell lines in vitro in a 
concentration-dependent manner. Flow cytometry demonstrated that DSF caused G0-G1 
growth arrest. DSF treatment led to increased ROS and lipid peroxidation levels relative to 
controls indicating the involvement of ferroptosis. Furthermore, DSF triggered lysosomal 
membrane permeabilization (LMP), a critical mechanism promoting cell death, in a ROS- 
dependent manner. Finally, DSF enhanced radiosensitivity of U251 and LN229 cells.
Discussion: Our findings indicated that DSF induced ferroptosis and LMP and enhanced the 
radiosensitivity of GBM cells. Therefore, DSF might have efficient antitumor activity in the 
treatment of human GBM.
Keywords: disulfiram, ferroptosis, lysosomal membrane permeabilization, ROS, 
glioblastoma
Introduction
Glioblastoma (GBM) is the most malignant primary tumor of the brain. Despite an 
aggressive treatment regimen which includes surgery, chemo- and radiotherapy, the 
prognosis of GBM patients is still poor. Thus, new treatments are desperately 
sought after.1
Resistance to apoptosis is one of the most important factors leading to the 
treatment failure of GBM.2 Apoptosis, one of the most studied programmed cell 
death (PCD) pathways, is the target of many antitumor treatments. Moreover, other 
types of PCD, including autophagy, necroptosis and pyroptosis have been discov-
ered and facilitated the search to overcome cancer treatment resistance.3 Ferroptosis 
is a newly discovered form of PCD.4 Characteristics include an accumulation of 
reactive oxygen species (ROS) resulting from intracellular iron accumulation and 
subsequent lipid peroxidation. Key morphological features of ferroptosis are shrun-
ken mitochondria and increased density of the mitochondrial membrane.5
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The cystine/glutamate antiporter (xc−)/glutathione 
(GSH)/glutathione peroxidase 4 (GPX4) axis is a critical 
pathway involved in regulating ferroptosis.6 xCT 
(SLC7A11) light chain, a subunit of system xc−, and GPX4, 
a selenoenzyme, are considered as key anti-ferroptosis 
proteins.7,8 Considering the role of ferroptosis in regulating 
cell death, ferroptosis might play an important role in tumor-
igenesis and tumor development. Erastin, a well-studied 
inducer of ferroptosis, has been shown to have remarkable 
anticancer activity in various tumor types.9–11 In addition, 
ferroptosis also enhances the antitumor properties of tradi-
tional chemo- and radiotherapy.9,12,13 As a result, ferroptosis 
is a promising target in anticancer treatment.
Cell death can also be induced by lysosomes, and this 
cell death type is called lysosomal membrane permeabili-
zation (LMP).14 In LMP, impaired lysosomal membranes 
allow the release of specific lysosomal enzymes into the 
cytosol, resulting in the hydrolyzation of various 
organelles.15 Among the many factors triggering LMP, 
ROS is the most important. Considering that the level of 
ROS is up-regulated in ferroptosis, LMP might have a role 
in the process. A recent study demonstrated that ferropto-
sis is a lysosomal cell death process,16 which supports this 
possibility.
Disulfiram (DSF) is traditionally used for the treatment 
of alcoholism and has been used clinically for many 
years.17 In recent years, an increasing number of studies 
have shown that DSF has promising antitumor properties 
and enhances sensitivity to radio- and chemotherapy in 
breast, bladder, and colorectal cancers.18–20 However, the 
mechanisms underlying its antitumor activity are not fully 
understood. Here, we investigated the antitumor properties 
of DSF in GBM cell lines. Our study demonstrates that 
DSF inhibits cell growth through the induction of ROS- 
dependent ferroptosis and LMP. Inhibiting ferroptosis 
counteracts LMP induced by DSF. These results highlight 
DSF as a promising antitumor agent for GBM and possi-
bly other tumor types.
Materials and Methods
Cell Culture
GBM cell lines U251 and LN229 were purchased from the 
Culture Collection of the Chinese Academy of Sciences 
(Shanghai, China) and cultured in DMEM (ThermoFisher 
Scientific; Waltham, MA, USA) supplemented with 10% 
fetal bovine serum (FBS; ThermoFisher Scientific).
Cell Viability Assay
U251 and LN229 cells (1.0 × 104 cells/well) were plated 
into 96-well plates and incubated overnight. DSF (0, 5, 10, 
15, 20, 30, 40, and 50 µM) was added to wells and cells 
were incubated with DSF for another 24 h. Cell viability 
was assessed with the CCK-8 assay. CCK-8 solution was 
added to each well, and colorimetric analysis was per-
formed on a microplate reader at 450 nm (PerkinElmer; 
San Jose, CA, USA).
EdU Assay
Cell proliferation was assessed with the EdU Assay Kit 
(Ribobio; Guangzhou, China) according to the manufac-
turer’s instructions. Briefly, U251 and LN229 cells (2.5 × 
104 cells/well) were seeded into 24-well, flat-bottomed 
plates and treated with 5 μM DSF or DMSO (vehicle 
control). Cells were incubated with EdU. Images were 
acquired under fluorescence microscopy (Leica DMi8; 
Wetzlar, Germany).
Cell Cycle Analysis
After treatment with 5 μM DSF or DMSO, U251 and 
LN229 cells were collected through trypsinization and 
fixed with 70% ethanol overnight. Cells were rinsed with 
PBS and incubated with propidium iodide (PI) supplemen-
ted with RNase (Becton Dickinson, San Diego, CA). Cell 
cycle analysis was performed on a C6 flow cytometer (BD 
Biosciences; San Jose, CA, USA).
Lipid Peroxidation and ROS Assay
Intracellular levels of lipid peroxidation/ROS were 
assessed using BODIPY581/591 C11/CellRox green dye 
(ThermoFisher Scientific). BODIPY581/591 C11 or 
CellRox green dye (5 μM; diluted in DMEM with 10% 
fetal bovine serum) was added to U251 and LN229 cells 
pretreated with 5 μM DSF or DMSO. Fluorescence was 
observed under confocal microscopy (Leica SP5 Confocal 
Microscope, Leica).
Iron Assay
The level of ferrous iron was tested by a colorimetric assay 
kit from Biovision (Milpitas, California, USA). Briefly, 
after treatment, U251 and LN229 cells were incubated 
with iron assay buffer. Supernatants were collected and 
incubated with iron probe. Then, samples were tested in a 
microplate reader at a wavelength of 593 nm 
(PerkinElmer).
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Western Blot Analysis
U251 and LN229 cells were treated with 2.5 μM, 5 μM and 10 
μM DSF or DMSO for 24 h. Cells were lysed in RIPA buffer 
(ThermoFisher Scientific) and lysates (20 µg) were analyzed 
on SDS-PAGE. Western blot analysis was performed as pre-
viously described.21 The following antibodies were used: 
GPX-4, x-CT, GAPDH and γ-H2AX (Abcam; 
Cambridge, UK).
Transmission Electron Microscopy
Transmission electron microscopy was used to examine the 
ultrastructure of U251and LN229 cells treated with 5 μM DSF 
or DMSO. Experiments were carried out as described 
previously.21 Images were obtained using a JEM-1200EX II 
electron microscope (JEOL; Tokyo, Japan).
Lysosomal Membrane Stability
Lysosomal membrane stability was assessed through two 
assays, acridine orange (AO; Sigma-Aldrich, USA) stain-
ing and GFP-fused galectin 3 (Obio, Shanghai, China) 
transient transfection.
For AO staining, U251 and LN229 cells were incu-
bated with AO (5 μg/mL) for 15 min, and treated with 5 
μM DSF or DMSO for 60 min. Fluorescence was detected 
under fluorescence microscopy with a Leica DMi8.
Transient transfections for GFP-fused galectin 3 were car-
ried out with lipofectamine 2000 reagent (ThermoFisher 
Scientific). Transfected U251 and LN229 cells were treated 
with 5 μM DSF or DMSO. Green dots in each treatment were 
counted under confocal microscopy with a Leica SP5 Confocal 
Microscope.
LysoTracker Staining
LysoTracker Red (66 nM; diluted in DMEM with 10% 
fetal bovine serum, ThermoFisher Scientific) was added to 
U251 and LN229 cells pretreated with 5 μM DSF or 
DMSO. Nuclei were stained with DAPI (ThermoFisher 
Scientific). Fluorescence was observed under confocal 
microscopy with a Leica SP5 Confocal Microscope.
Live/Dead Cell Viability Assay
Cytotoxic effects were assessed using a Live/Dead cell 
viability assay kit (Thermo Fisher Scientific). U251 and 
LN229 cells were divided into four treatment groups: 
DMSO, 5 µM DSF, 4 Gy irradiation at a dose rate of 1.8 
Gy/min in a linear accelerator (Primus Hi, Siemens 
Medical Instruments; Berlin, Germany), and 5 µM DSF 
combined with 4 Gy irradiation. Cells were incubated with 
a combination of 5 µL calcein AM and 20 µL ethidium 
homodimer-1 staining solution (diluted in DMEM with 
10% fetal bovine serum). Green and red fluorescence 
were observed under fluorescence microscopy with a 
Leica DMi8 fluorescence microscope.
Immunofluorescence
DNA damage was determined using immunofluorescence 
staining of γ-H2AX foci. U251 and LN229 cells were treated 
as described in 2.8. Cells were incubated with γ-H2AX anti-
body (Cell Signaling Technology; Danvers, MA, USA) and 
Alexa Fluor 594 conjugated goat anti-rabbit secondary anti-
body (Abcam; Cambridge, UK). Red dots corresponding to γ- 
H2AX were counted under a Leica TCS SP5 Confocal Laser 
Scanning Microscope (Leica Microsystem).
Statistical Analysis
Unpaired t-tests were performed using GraphPad Prism 
software program (Version 6.07; La Jolla, CA, USA). 
Results are presented as the mean ± SE. P-values < 0.05 
were considered statistically significant.
Results
DSF Inhibits Cell Growth of GBM Cells
To begin to determine whether DSF might inhibit GBM, U251 
and LN229 cells were treated with DSF in culture, and cell 
viability and proliferation assays were performed. Growth 
curves were generated for the two cell lines using colorimetric 
data from the CCK-8 assay and showed that cell viability of 
U251 and LN229 cells decreased under treatment with DSF in 
a dose-dependent manner (Figure 1A). The IC50 for U251 and 
LN229 was 30 μM and 13.5 μM, respectively (Figure 1A). 
Thus, LN229 cells were more sensitive to DSF than U251 
cells. EdU incorporation also showed that DSF inhibited cell 
growth. Treatment with 5 μM DSF led to a decrease in the 
number of EdU positive cells compared with cells treated with 
DMSO (38.67% ± 2.028% vs 23.67% ± 1.202% for U251; 
39.67% ± 1.333% vs 13.00% ± 1.155% for LN229; Figure 1B 
and C).
Flow cytometry was used to analyze cell cycle parameters 
of U251 and LN229 cells treated with DSF or the vehicle 
control DMSO. The percentage of cells in G0-G1 increased 
in cells treated with 5 μM DSF relative to controls (57.73% vs 
63.05% for U251; 59.7% vs 66% for LN229); Figure 1D and 
E. All together, these results indicated that DSF inhibited 
growth of GBM cells in vitro.
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DSF Induces Ferroptosis in U251 and 
LN229 Cells
We next investigated whether DSF induced ferroptosis in 
GBM cells. Up-regulation of lipid peroxidation is one of the 
characteristics of ferroptosis. Oxidation of the free radical 
sensor BODIPY581/591 C11 dye shifts fluorescence of the dye 
from red to green. Under DSF treatment, red fluorescence of 
the dye decreased while green fluorescence increased in both 
U251 and LN229 cells (Figure 2A). These data suggested that 
DSF increased lipid peroxidation. CellRox Green Reagent, 
which detects oxidative stress, exhibited bright green fluores-
cence in DSF treated GBM cells. These results indicated that 
DSF led to increased total ROS in U251 and LN229 cells 
(Figure 2B and C). We also tested the levels of ferrous iron 
with a colorimetric assay kit and results showed that DSF 
increased levels of ferrous iron (Figure 2D). Levels of proteins 
that block ferroptosis, xCT and GPX-4, decreased in the 
presence of DSF in a dose-dependent manner (Figure 2E). 
Transmission electron microscopy also revealed the shrunken 
morphology of mitochondria in DSF treated GBM cells (red 
arrows, Figure 2F) and the enhanced density of mitochondrial 
membranes (Figure 2F). Iron chelator deferoxamine mesylate 
(DFO) and ferroptosis inhibitor ferrostatin-1 (Fer-1) were used 
to verify whether these results were iron- and ferroptosis- 
dependent. We found that DFO and Fer-1 inhibited DSF- 
induced up-regulation of lipid peroxidation (Figure 2G) and 
cytotoxic effect (Figure 2H). All together, these data demon-
strated that DSF triggered ferroptosis in GBM.
DSF Causes Lysosomal Membrane 
Permeabilization in GBM Cells
A recent study demonstrated that ferroptosis is a lyso-
some-dependent cell death process. Lysosomal membrane 
permeabilization (LMP) is one mechanism inducing cell 
Figure 1 DSF inhibits cell growth of GBM cells (A) Growth curves generated with colorimetric data (O.D. 450 nm) from the CCK-8 assay. U251 and LN229 cells were 
treated with increasing concentrations of DSF for 24 h. The IC50 for U251 and LN229 was 30 μM and 13.5 μM, respectively. (B) Fluorescence images for EdU incorporation 
at 5 μM DSF and DMSO (vehicle control) for 24 h in U251 and LN229 cells. (C) Quantification of EdU positive cells treated with DMSO (vehicle control) and 5 μM DSF in B. 
(D) Cell cycle analysis of U251 and LN229 cells treated with DMSO (vehicle control) and 5 μM DSF for 24 h. (E) Quantification of cell cycle parameters G0-G1, S, and G2-M 
obtained from flow cytometric analysis in D. *P < 0.05; **P < 0.01; ***P < 0.001; scale bars = 50 µm.
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death and the most studied form of lysosome-dependent 
cell death. When LMP occurs, lysosomal contents, includ-
ing many acid proteases, leak into the cytoplasm, destroy-
ing critical proteins and resulting in cell death. We 
therefore tested whether DSF triggered LMP in GBM 
cells. Acridine orange (AO), a cell-permeant dye, is lyso-
somotropic, and emits red fluorescence at high concentra-
tions and green fluorescence at low concentrations. Intact 
Figure 2 DSF induces ferroptosis in GBM cells. (A) Representative fluorescence images of BODIPY581/591 C11 staining of U251 and LN229 cells treated with DMSO (vehicle control) 
and 5 μM DSF for 24 h. (B) Representative fluorescence images of CellRox Green staining of U251 and LN229 cells treated with DMSO (vehicle control) and 5 μM DSF. (C) 
Quantification of fluorescence in (B). (D) Levels of ferrous iron in U251 and LN229 cells treated with DMSO (vehicle control) and 5 μM DSF. (E) Western blot analysis of lysates 
prepared from U251 and LN229 cells treated with 0, 2.5, 5 and 10 μM DSF for 24 h to detect levels of protein inhibitors of ferroptosis, xCT and GPX-4. GAPDH was used as a loading 
control. The xCT/GAPDH and GPX-4/GAPDH ratios were calculated using ImageJ (National Institutes of Health, version 1.52r). (F) Transmission electron microscopy image showing 
the ultrastructure of U251 cells treated with DMSO (vehicle control) or 5 μM DSF. Normal mitochondria in control cells highlighted with the white arrows; shrunken mitochondria and 
the enhanced density of mitochondrial membrane highlighted with red arrows in DSF treated U251 cells. (G) BODIPY581/591 C11 staining of U251 and LN229 cells treated with DMSO, 5 
μM DSF, 50 μM iron chelator deferoxamine mesylate (DFO) + 5 μM DSF, 2 μM Ferrostatin-1 (Fer-1) + 5 μM DSF. (H) LDH release assay was used to test the cytotoxic effect of U251 and 
LN229 cells treated with DMSO, 10 μM DSF, 50 μM iron chelator deferoxamine mesylate (DFO) + 10 μM DSF, 2 μM Ferrostatin-1 (Fer-1) + 10 μM DSF. **P < 0.01; ***P < 0.001; ****P < 
0.0001; Size bars in (A, B and G) = 50 µm, in (E) = 0.5 µm.
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lysosomes emit red fluorescence after AO staining. When 
membranes are compromised, the concentration of AO 
decreased, and thus red fluorescence decreases. The red 
fluorescence of AO decreased in U251 and LN229 cells 
treated with DSF compared with untreated controls 
(Figure 3A).
Galectin 3, a β-galactoside binding lectin, accumulates 
on luminal glycoproteins when the membranes of endo-
somes or lysosomes are impaired. GBM cells were there-
fore transfected with a GFP-fused galectin 3 (EGFP-Gal3) 
plasmid to determine whether DSF induced LMP. EGFP- 
Gal3 appeared in fluorescent puncta in the DSF treated 
cells but only as a diffuse fluorescence in control cells 
(Figure 3B and C). LysoTracker Red is another lysosomo-
tropic dye used to test whether lysosomes retain their 
function. Intact lysosomes have an acidic lumen which 
emit red fluorescence when stained with LysoTracker 
Red. When lysosomes are impaired, the intensity of the 
red fluorescence decreases. Red fluorescence decreased 
significantly in DSF-treated U251 and LN229 cells, indi-
cating that DSF interfered with the function of lysosomes 
in GBM cells (Figure 3D). These data indicated that DSF 
led to LMP in GBM cells in culture.
DSF Induces LMP in a ROS-Dependent 
Manner
Many factors induce LMP, such as ROS and lysosomotro-
pic reagents. Because DSF induced ROS in GBM cells, we 
next investigated whether DSF induces LMP in a ROS- 
Figure 3 DSF induces lysosomal membrane permeabilization in GBM cells. (A) Fluorescence images of acridine orange staining of DSF treated U251 and LN229 cells 
compared with controls (DMSO, vehicle control). Red fluorescence is associated with high concentrations of acridine orange, while green fluorescence is associated with 
reduced concentrations of acridine orange. (B) Fluorescence images of U251 and LN229 cells treated with DSF and transfected with EGFP-Gal3 construct (green 
fluorescence). Green puncta result from the collection of EGFP-Gal3 collection on compromised lysosomes. (C) Quantification of green puncta in (B). (D) Fluorescence 
images of LysoTracker Red staining of DSF treated U251 and LN229 cells. ***P < 0.001; scale bars in (A) = 50 µm, in (B and D) = 10 µm.
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dependent manner. Cells were therefore exposed to glu-
tathione (GSH), a ROS scavenger, to inhibit ROS produc-
tion in GBM cells under treatment with DSF. In U251 and 
LN229 cells transfected with EGFP-Gal3, GSH prevented 
the appearance of green puncta induced by DSF treatment 
(Figure 4A and B). Cells were also treated with ferrostatin 
(Fer-1), a small molecule inhibitor of ferroptosis, to 
explore whether DSF-induced LMP was ferroptosis depen-
dent. Fer-1 also prevented the increase in EGFP-Gal3 
puncta induced by DSF in U251 and LN229 cells 
(Figure 4A and B). All together, these results indicated 
that DSF-induced LMP in GBM cells was ferroptosis 
dependent.
DSF Increased Radiosensitivity in GBM 
Cells
In our previous work, we found that Lys05, an LMP 
inducer, increased the radiosensitivity of U251 and 
LN229 cells. In many other studies, DSF was also found 
to enhance the antitumor effect of radiotherapy. We there-
fore investigated whether DSF enhanced the radiosensitiv-
ity of GBM cells. Using a Live/Dead cell viability assay, 
we found that radiation combined with DSF led to 
increased cell death compared with radiation or DSF treat-
ment alone (Figure 5A and B).
DNA damage is the main cause of cell death in 
response to radiation, and double strand breaks (DSBs) 
are the most lethal of the various types of DNA damage 
induced by radiation exposure. We therefore used immu-
nofluorescence staining of γ-H2AX, a well-known marker 
of DSBs, to determine whether DSF sensitized cells to 
radiation treatment. U251 and LN229 cells exposed to 
both radiation and DSF exhibited increased staining of γ- 
H2AX relative to cells treated with either DSF treatment 
alone or controls (Figure 5C and D). Western blot analysis 
of γ-H2AX also showed that DSF combined with radiation 
Figure 4 DSF induces LMP in a ROS-dependent manner. (A) Fluorescence images of cells transfected with EGFP-Gal3. U251 and LN229 cells were treated with DSF and 
inhibitors of ferroptosis, 5 mM GSH or 2 µM ferrostatin-1 (Fer-1), and compared with DSF treatment alone. (B) Quantification of green punta in (A). **P < 0.01; ***P < 
0.001; size bars = 50 µm.
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led to more DNA damage compared with other groups 
(Figure 5E). All together, these data suggested that DSF 
enhanced radiosensitivity in GBM cells in culture.
Discussion
DSF has been used for the treatment of alcoholism since 1948. 
An increasing number of studies have reported that DSF 
exhibits dramatic anticancer activity in various cancer cell 
types. DSF has also been shown to enhance the antitumor 
properties of chemotherapy and radiotherapy.18–20,22,23 Here, 
we showed that DSF displays efficient anti-glioma activity by 
decreasing cell viability, inhibiting cell proliferation and caus-
ing in G0-G1 cell cycle arrest. DSF also enhanced the radio-
sensitivity of GBM cells in vitro. Many studies have 
demonstrated that DSF possesses copper-dependent anticancer 
activity and that copper greatly enhances the antitumor efficacy 
of DSF.24 In fact, the IC50 of DSF in several tumor types was 
decreased when combined with copper.25 Further study is 
therefore warranted to determine whether the combination of 
DSF with copper is more efficient in triggering ferroptosis and 
LMP in GBM.
Resistance to apoptosis is one of the most important 
factors contributing to the failure of anti-cancer treatment.-
26 Discovering new methods to overcome apoptotic resis-
tance might tremendously advance the treatment of cancer. 
Ferroptosis is a newly-discovered mechanism of pro-
grammed cell death.3 Iron accumulation up-regulates 
ROS production, which results in lipid peroxidation and 
subsequent cell death.27 Most studies have shown that 
DSF kills cancer cells by causing apoptosis.20,28 Until 
now, only a single study has shown that DSF induces 
ferroptosis in cancer, specifically nasopharyngeal cancer.17 
In our study, DSF treatment significantly increased the 
levels of lipid peroxidation and ROS in GBM cells. The 
protein levels of xCT and GPX-4, two important antiox-
idant proteins, were also decreased. Finally, the 
Figure 5 DSF enhances the radiosensitivity of GBM cells. (A) Fluorescence images of the Live/Dead staining assay (green fluorescence, live; red fluorescence, dead) 
performed on U251 and LN229 cells treated with DSF (5 µM), radiation (4 GY, IR) or a combination of DSF and radiation. (B) Quantification of dead cells (red fluorescence) 
in (A). (C) Immunofluorescence staining of γ-H2AX (red fluorescence) to determine the double strand breaks (DSBs) caused by DSF, radiation (IR) or a combination of DSF 
and radiation. (D) Quantification of red puncta associated with γ-H2AX in (C). (E) Western blot analysis of lysates prepared from U251 and LN229 cells treated with DSF (5 
µM), radiation (4 GY, IR) or a combination of DSF and radiation. GAPDH was used as a loading control. The γ-H2AX/GAPDH ratio was calculated using ImageJ. **P < 0.01; 
***P < 0.001; size bars in (A) = 50 µm, in (D) = 10 µm.
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morphology of the mitochondria in the presence of DSF 
was consistent with the cellular process of ferroptosis. 
Thus, DSF could be classified as an inducer of ferroptosis 
in GBM cells.
ROS is also a well-known inducer of LMP.29 When 
LMP occurs, lysosomal contents, including many acid 
proteases, leak into the cytoplasm, resulting in cell death.30 
Our work demonstrated that DSF also triggered LMP in 
U251 and LN229 cells and that GSH, a ROS scavenger, 
interfered with DSF-induced LMP. In addition, ferrostatin- 
1, a small molecule inhibitor of ferroptosis, prevented 
DSF-induced LMP. Thus, ROS might be a key link 
between ferroptosis and LMP.
Despite aggressive treatment of GBM with a combina-
tion of surgery, and radio- and chemotherapy, patient prog-
nosis remains poor. New therapies are urgently needed. 
Yet conventional drug development is time consuming and 
expensive. As a result, drug repurposing has gained 
increasing attention as an approach to the identification 
of viable anticancer therapies.31 In a previous study, we 
found that trifluoperazine, an antipsychotic drug in the 
treatment of schizophrenia, increased the radiosensitivity 
of GBM both in vitro and in vivo.21 Many drugs that have 
been used in the clinic for many years may have mechan-
isms of action other than their main indications, and these 
drugs have well-established clinical safety profiles.32
Conclusion
In this study, we found that DSF had significant antitumor 
activity in GBM cells through the induction of ferroptosis. 
DSF also enhanced the sensitivity of GBM cells to radio-
therapy. For the first time, our study demonstrates that 
DSF triggers LMP in a ROS-dependent manner. ROS 
may thus be a key link between ferroptosis and LMP. 
Altogether, our study revealed DSF as a promising anti-
tumor compound in the treatment of GBM. However, 
further study of these properties of DSF and other inducers 
of ferroptosis might also contribute to the development of 
novel treatments for other tumor types.
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